- Conditions
- Severe Acute Respiratory Syndrome, Respiratory Failure, Acute Respiratory Distress Syndrome
- Interventions
- Alteplase 50 MG [Activase]
- Drug
- Lead sponsor
- Denver Health and Hospital Authority
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 9
- States / cities
- La Jolla, California • Aurora, Colorado • Denver, Colorado + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 2,065
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hypertrophic Cardiomyopathy
- Interventions
- Echo and myocardial contrast echocardiography perfusion imaging
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 19 Years to 80 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Kawasaki Disease, Coronary Aneurysm
- Interventions
- Doxycycline, Placebo
- Drug
- Lead sponsor
- Hawaii Pacific Health
- Other
- Eligibility
- 1 Month to 21 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2026
- U.S. locations
- 1
- States / cities
- Honolulu, Hawaii
- Conditions
- Crohn Disease
- Interventions
- Ustekinumab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Hartford, Connecticut • Atlanta, Georgia + 5 more
- Conditions
- Solid Tumor, Non Small Cell Lung Cancer, Neuroendocrine Carcinoma, Renal Cell Carcinoma (RCC)
- Interventions
- VSV-IFNβ-NIS, Pembrolizumab, ipilimumab + nivolumab
- Biological
- Lead sponsor
- Vyriad, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota • Cleveland, Ohio
- Conditions
- Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Anemia, Neonatal
- Interventions
- Erythropoietin, Sham Comparator
- Drug · Other
- Lead sponsor
- NICHD Neonatal Research Network
- Network
- Eligibility
- 24 Hours to 96 Days
- Enrollment
- 318 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1997 – 2000
- U.S. locations
- 9
- States / cities
- New Haven, Connecticut • Washington D.C., District of Columbia • Atlanta, Georgia + 6 more
- Conditions
- Melanoma
- Interventions
- TAK-580, TAK-202, vedolizumab, nivolumab, ipilimumab
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 14
- States / cities
- Tucson, Arizona • Los Angeles, California • San Francisco, California + 10 more
- Conditions
- Metastatic Pancreatic Cancer
- Interventions
- Ixabepilone, Cetuximab
- Drug
- Lead sponsor
- R-Pharm
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 9
- States / cities
- Washington D.C., District of Columbia • Jacksonville, Florida • Miami, Florida + 6 more
- Conditions
- Acute Leukemia, Immune Deficiency Disorder, Congenital Hematological Disorder, Metabolism Disorder, Aplastic Anemia, Myelodysplastic Syndromes, Chronic Leukemia, Lymphoma, Multiple Myeloma, Solid Tumor
- Interventions
- Total Body Irradiation 1200 cGy, Total Body Irradiation 200 cGy, Cyclophosphamide, Mesna, Cord Blood Infusion, Busulfan, Fludarabine, Melphalan
- Radiation · Drug · Procedure
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 2 Months to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Sickle Cell Disease, Sickle Cell Anemia
- Interventions
- N-Acetylcysteine
- Drug
- Lead sponsor
- Bloodworks
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Gastric Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
- Interventions
- TRK-950, Ramucirumab, Paclitaxel
- Biological · Drug
- Lead sponsor
- Toray Industries, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 14
- States / cities
- Duarte, California • Irvine, California • Santa Monica, California + 6 more
- Conditions
- Hemophilia A
- Interventions
- BAY94-9027
- Biological
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 12 Years to 65 Years · Male only
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 14
- States / cities
- Tucson, Arizona • Sacramento, California • San Diego, California + 11 more
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myeloid Leukemia
- Interventions
- Clofarabine, Busulfan, Fludarabine, Stem Cell Infusion, Thymoglobulin (ATG), Filgrastim
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Up to 60 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Solid Cancers
- Interventions
- GDC-0980, bevacizumab, capecitabine, mFOLFOX6
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Aurora, Colorado • Rochester, Minnesota
- Conditions
- Prostate Cancer, Pain
- Interventions
- Azacitidine, Docetaxel, Prednisone, GADD45α methylation and expression analysis, Pegfilgrastim, Filgrastim
- Drug · Genetic
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 120 Years · Male only
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2015
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Peripheral Intravenous Catheters
- Interventions
- ViaValve Safety IV Catheter, Insyte Autoguard BC [Blood Control] Shielded IV Catheter
- Device
- Lead sponsor
- Smiths Medical, ASD, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Multiple Myeloma
- Interventions
- AT7519M, Bortezomib
- Drug
- Lead sponsor
- Astex Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • New York, New York • Milwaukee, Wisconsin
- Conditions
- Cancer, Solid Tumor, Colorectal Cancer, Pancreas Cancer, Non Small Cell Lung Cancer, Head and Neck Cancer, Gynecologic Cancer, Skin Cancer, Kidney Cancer
- Interventions
- DK210 (EGFR), Radiation therapy, Immune checkpoint blockers, Chemotherapy
- Biological · Radiation · Drug
- Lead sponsor
- DEKA Biosciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 7
- States / cities
- Duarte, California • Manhasset, New York • Oklahoma City, Oklahoma + 3 more
- Conditions
- Metabolic Syndrome, Vascular Injury, Ischemic Preconditioning, Endothelial Function (reactive Hyperemia), Endothelial Dysfunction
- Interventions
- Ischemic preconditioning, Intravenous lactate infusion, No ischemic preconditioning (control), Normal Saline Infusion (Placebo), Ischemic preconditioning and intravenous lactate
- Procedure · Drug · Combination Product
- Lead sponsor
- Gary Van Guilder
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Gunnison, Colorado
- Conditions
- Perinatal Arterial Ischemic Stroke
- Interventions
- Autologous Cord Blood Infusion
- Biological
- Lead sponsor
- James Baumgartner, MD
- Other
- Eligibility
- 6 Weeks to 6 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Red Blood Cell Transfusion
- Interventions
- Fresh red blood cell (RBC) transfusion, Storage-aged red blood cell (RBC) transfusion, Electronic infusion pump
- Biological · Device
- Lead sponsor
- Emory University
- Other
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer
- Interventions
- DS-8201a, T-DM1
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 126
- States / cities
- Anaheim, California • Baldwin Park, California • Bellflower, California + 94 more
- Conditions
- Prematurity, Iron-deficiency, Iron Deficiency Anemia, Iron Malabsorption
- Interventions
- Darbepoetin Alfa, Low Molecular Weight Iron Dextran, Ferumoxytol injection, Oral iron supplements
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- Up to 3 Days
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Acute Ischemic Stroke
- Interventions
- natalizumab, Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 19
- States / cities
- San Diego, California • Gainesville, Florida • Kansas City, Kansas + 16 more